ANCA stands for anti-neutrophil cytoplasmic antibodies, a type of autoantibody that mistakenly attacks proteins inside your own white blood cells. These antibodies are most significant because they can trigger inflammation in small blood vessels throughout the body, a group of conditions collectively called ANCA-associated vasculitis. If your doctor ordered an ANCA test, they’re likely investigating whether your immune system is behind symptoms affecting your kidneys, lungs, sinuses, or other organs.
How ANCA Antibodies Work
Neutrophils are white blood cells that normally fight infections. They contain powerful enzymes stored in small internal compartments. ANCA antibodies target two of these enzymes specifically: proteinase 3 (PR3) and myeloperoxidase (MPO). Under normal circumstances, these enzymes stay tucked inside the cell and help destroy bacteria. The problem starts when ANCA antibodies latch onto them.
The process unfolds in stages. An infection or other trigger causes the immune system to release inflammatory signals that “prime” neutrophils, pushing PR3 or MPO to the cell surface where ANCA can reach them. Once ANCA binds to these exposed enzymes, the neutrophil goes into overdrive, releasing destructive compounds including oxygen radicals, tissue-dissolving enzymes, and sticky web-like structures called neutrophil extracellular traps. All of this damage gets directed at the walls of small blood vessels, causing inflammation, tissue death, and organ damage.
The Two Types of ANCA
ANCA testing distinguishes between two patterns based on which protein the antibodies target:
- C-ANCA (PR3-ANCA): Targets proteinase 3. This pattern is strongly linked to granulomatosis with polyangiitis (GPA, formerly called Wegener’s granulomatosis). PR3-ANCA is about 90% sensitive for GPA, meaning most people with this disease will test positive. This type also carries a higher relapse rate: about 44% of patients with PR3-ANCA experience disease flares over time.
- P-ANCA (MPO-ANCA): Targets myeloperoxidase. This pattern is more commonly associated with microscopic polyangiitis (MPA) and has a lower relapse rate of roughly 13%.
The “C” and “P” refer to how the antibodies look under a microscope during testing. C-ANCA creates a diffuse, grainy pattern across the cell’s cytoplasm, while P-ANCA clusters around the nucleus in a ring-like pattern.
Conditions Linked to Positive ANCA
The three main diseases grouped under ANCA-associated vasculitis are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, previously called Churg-Strauss syndrome). All three involve inflammation of small blood vessels, but they affect the body differently.
GPA typically hits the upper and lower respiratory tract and the kidneys. People often notice bloody nasal discharge, chronic sinus problems, or ear infections early on. Lung involvement can cause nodules or bleeding into the air sacs. Kidney damage may show up as blood or protein in the urine and can progress to rapid kidney failure if untreated. In severe, long-standing cases, destruction of nasal cartilage can cause a visible change in the shape of the nose known as saddle nose deformity.
MPA primarily targets the kidneys. Kidney involvement is almost universal in MPA and typically presents as acute kidney failure. Lung problems are less common than in GPA but can include severe bleeding from tiny blood vessels in the lungs. MPA can also cause scarring in the lungs over time.
EGPA stands apart from the other two because of its strong association with asthma, chronic sinus inflammation, and elevated levels of a white blood cell type called eosinophils. Only about 30% to 40% of people with EGPA test positive for ANCA. Those who do tend to have more classic vasculitis symptoms like kidney inflammation and nerve damage, while those who test negative are more likely to develop heart inflammation.
Common Symptoms That Prompt Testing
ANCA-associated vasculitis often starts with vague, general symptoms: persistent fatigue, unexplained fevers, muscle aches, and unintentional weight loss. These can drag on for weeks or months before more specific organ involvement becomes apparent.
The symptoms that typically push a doctor toward ordering an ANCA test include coughing up blood, blood in the urine, sudden worsening of kidney function, recurring sinus infections that don’t respond to antibiotics, numbness or weakness in the hands or feet, skin rashes (especially purplish spots on the legs), and unexplained shortness of breath. Because vasculitis can affect nearly any organ, the presentation varies widely from person to person.
How the ANCA Test Works
ANCA testing is a blood draw, nothing more. In the lab, the sample is analyzed using one or both of two methods. The older approach, indirect immunofluorescence (IIF), involves exposing your blood to prepared neutrophils on a glass slide and looking for glowing antibody patterns under a fluorescent microscope. The newer approach uses antigen-specific immunoassays that directly measure the amount of PR3-ANCA or MPO-ANCA in your blood.
A 2016 evaluation by the European Vasculitis Study Group found that modern immunoassays perform as well as or better than the traditional microscope method, with less variability between labs. Many centers now use these newer tests as the primary screening tool rather than starting with immunofluorescence. The 2017 international consensus on ANCA testing reflects this shift.
Reading Your Results
For PR3 antibodies (C-ANCA), levels above 3.0 IU/mL are considered positive, 2.0 to 3.0 is equivocal, and below 2.0 is negative. For MPO antibodies (P-ANCA), above 5.0 IU/mL is positive, 3.5 to 5.0 is equivocal, and below 3.5 is negative. ANCA serology is positive in about 90% of GPA and MPA cases, so a negative result doesn’t completely rule out vasculitis, and a positive result doesn’t confirm it on its own.
What a Positive Result Doesn’t Always Mean
A positive ANCA test is not automatic proof of vasculitis. Several medications can trigger ANCA production and even cause a drug-induced form of vasculitis. Anti-thyroid drugs and TNF inhibitors are the most commonly implicated, but the list spans nearly every drug category, including certain antibiotics (vancomycin, minocycline, nitrofurantoin), blood pressure medications (hydralazine), gout treatments (allopurinol), and even cocaine contaminated with a deworming agent called levamisole.
In drug-induced cases, symptoms typically improve after stopping the offending medication. Other non-vasculitic conditions, including inflammatory bowel disease and certain infections, can also produce positive ANCA results. This is why doctors interpret ANCA results alongside symptoms, imaging, and sometimes a tissue biopsy before making a diagnosis.
Monitoring ANCA Levels Over Time
Once vasculitis is diagnosed, ANCA levels become a useful tracking tool, though not a perfect one. Research on long-term management found that 24 of 27 disease relapses occurred when ANCA was detectable, and in 21 of those cases, levels were either high or climbing. Patients who still had detectable ANCA one year or more after treatment were at particular risk for relapse.
That said, the relationship between ANCA levels and flares isn’t always straightforward. Some patients maintained high ANCA levels for over a year, and in one case 11 years, without experiencing a relapse. Rising or persistently elevated levels signal the need for closer monitoring and possibly continued treatment, but they aren’t used as the sole reason to change therapy. Doctors weigh ANCA trends alongside symptoms, blood work, and urine tests to get the full picture.
How ANCA-Associated Vasculitis Is Treated
Treatment happens in two phases: knocking down the active disease (induction) and keeping it from coming back (maintenance). For serious or organ-threatening disease, current European guidelines recommend high-dose steroids combined with either rituximab or cyclophosphamide to suppress the immune system and stop the inflammatory attack. Rituximab is generally preferred when the disease has relapsed. For milder cases that aren’t threatening organs, steroids plus rituximab remains the standard, with methotrexate as an alternative.
Once the disease is in remission, maintenance therapy aims to prevent flares while minimizing long-term side effects from steroids. Rituximab is the recommended maintenance option. Azathioprine and methotrexate serve as alternatives. The duration of maintenance treatment varies, but most people remain on some form of immune-suppressing therapy for at least two years, sometimes longer depending on their relapse risk and ANCA type. Because PR3-ANCA carries a relapse rate more than three times higher than MPO-ANCA, people with that antibody pattern often require longer or more aggressive maintenance.